“Gilead delivered another strong quarter of revenue growth … in our base business driven by HIV, Oncology and Liver Diseases,” CEO Daniel O’Day said in a statement, adding that the pharma is looking forward to a year of promising pipeline updates, particularly regarding its long-acting HIV and cancer programs.
Pfizer will go toe-to-toe with CSL Behring following the FDA’s Friday approval of its hemophilia B gene therapy Beqvez and will launch a warranty program based on the durability of response.
Humira maintained its blockbuster status and market share dominance in the first quarter of 2024, but experienced a drop in sales as biosimilar competition heated up, AbbVie reported on Friday.
Leading pharmaceutical business and marketing publication Med Ad News has announced the winners of the 2024 Manny Awards. The honors were presented at a black-tie gala held last night at Pier Sixty, Chelsea Piers in New York City.
The U.S. health regulator has sent a warning letter to Cardinal Health (CAH.N) after an inspection of its facility in Illinois found the company was marketing and distributing unapproved devices made by a Chinese manufacturer.
Today the company reported a first-quarter loss as charges related to its acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a 5% increase in revenue.
